TAXUS PERSEUS Workhorse
NCT00484315
Completed
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries of 2.75 mm to 4.0 mm diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2014
Locations: Union Memorial Hospital, Baltimore, Maryland +1 locations
Conditions: Coronary Artery Disease
Register for Updates
Treatment With Pazopanib for Neoadjuvant Breast Cancer
NCT00849472
Completed
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/30/2014
Locations: GSK Investigational Site, Baltimore, Maryland
Conditions: Neoplasms, Breast
Register for Updates
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
NCT00596830
Terminated
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2013
Locations: Pfizer Investigational Site, Baltimore, Maryland +1 locations
Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Register for Updates
Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
NCT00003591
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients who have nonmetastatic, unresectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2013
Locations: Anne Arundel Oncology Center, Annapolis, Maryland +5 locations
Conditions: Pancreatic Cancer
Register for Updates
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
NCT00828841
Completed
This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be tested further. The study will also look at what side effects may occur.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2013
Locations: Not set, Baltimore, Maryland +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
NCT00147537
Completed
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2013
Locations: Pfizer Investigational Site, Baltimore, Maryland
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
NCT00583830
Completed
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2013
Locations: University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland +1 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach
NCT00009880
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy plus radiation therapy with and without fluorouracil in treating patients who have cancer of the esophagus or stomach.
Gender:
ALL
Ages:
All
Trial Updated:
07/17/2013
Locations: Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00054392
Withdrawn
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIIB, stage IV, or re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2013
Locations: Annapolis Oncology Center, Annapolis, Maryland +2 locations
Conditions: Lung Cancer
Register for Updates
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002568
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of paclitaxel and cisplatin with or without surgery in treating patients with stage III ovarian epithelial cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/08/2013
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland
Conditions: Ovarian Cancer
Register for Updates
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00003691
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of doxorubicin and cisplatin with or without paclitaxel and G-CSF in treating patients who have stage III, stage IV, or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2013
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland +2 locations
Conditions: Endometrial Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer
NCT00003378
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients with previously untreated stage III or stage IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
07/08/2013
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland +2 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates